99 related articles for article (PubMed ID: 23770158)
1. A multicenter, open-label, noncomparative screening study of enzastaurin in adult patients with non-Hodgkin lymphomas.
Forsyth CJ; Gomez-Almaguer D; Camargo JF; Eliadis PE; Crespo-Solis E; Pereira J; Gutierrez-Aguirre CH; Rivas-Vera S; Roberson S; Lin B; Smith NV; Hamid O
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):398-403. PubMed ID: 23770158
[TBL] [Abstract][Full Text] [Related]
2. Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma.
Schwartzberg L; Hermann R; Flinn I; Flora D; Hsi ED; Hamid O; Shi P; Lin BK; Myrand SP; Nguyen TS; Dreyling M
Br J Haematol; 2014 Jul; 166(1):91-7. PubMed ID: 24673609
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Robertson MJ; Kahl BS; Vose JM; de Vos S; Laughlin M; Flynn PJ; Rowland K; Cruz JC; Goldberg SL; Musib L; Darstein C; Enas N; Kutok JL; Aster JC; Neuberg D; Savage KJ; LaCasce A; Thornton D; Slapak CA; Shipp MA
J Clin Oncol; 2007 May; 25(13):1741-6. PubMed ID: 17389337
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.
Zinzani PL; Pellegrini C; Merla E; Ballerini F; Fabbri A; Guarini A; Pavone V; Quintini G; Puccini B; Vigliotti ML; Stefoni V; Derenzini E; Broccoli A; Gandolfi L; Quirini F; Casadei B; Argnani L; Baccarani M
Hematol Oncol; 2013 Dec; 31(4):179-82. PubMed ID: 23108928
[TBL] [Abstract][Full Text] [Related]
5. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
Pettengell R; Coiffier B; Narayanan G; de Mendoza FH; Digumarti R; Gomez H; Zinzani PL; Schiller G; Rizzieri D; Boland G; Cernohous P; Wang L; Kuepfer C; Gorbatchevsky I; Singer JW
Lancet Oncol; 2012 Jul; 13(7):696-706. PubMed ID: 22652183
[TBL] [Abstract][Full Text] [Related]
6. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
7. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
Borchmann P; Morschhauser F; Parry A; Schnell R; Harousseau JL; Gisselbrecht C; Rudolph C; Wilhelm M; Günther H; Pfreundschuh DM; Camboni G; Engert A
Haematologica; 2003 Aug; 88(8):888-94. PubMed ID: 12935976
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).
Rigacci L; Puccini B; Cortelazzo S; Gaidano G; Piccin A; D'Arco A; Freilone R; Storti S; Orciuolo E; Zinzani PL; Zaja F; Bongarzoni V; Balzarotti M; Rota-Scalabrini D; Patti C; Gobbi M; Carpaneto A; Liberati AM; Bosi A; Iannitto E
Ann Hematol; 2012 Jul; 91(7):1013-22. PubMed ID: 22349722
[TBL] [Abstract][Full Text] [Related]
10. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
Ghobrial IM; Munshi NC; Harris BN; Shi P; Porter NM; Schlossman RL; Laubach JP; Anderson KC; Desaiah D; Myrand SP; Wooldridge JE; Richardson PG; Abonour R
Am J Hematol; 2011 Jul; 86(7):573-8. PubMed ID: 21630305
[TBL] [Abstract][Full Text] [Related]
11. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
Oh Y; Herbst RS; Burris H; Cleverly A; Musib L; Lahn M; Bepler G
J Clin Oncol; 2008 Mar; 26(7):1135-41. PubMed ID: 18309949
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660
[TBL] [Abstract][Full Text] [Related]
15. Lymphoma of the ocular adnexa: A study of 353 cases.
Ferry JA; Fung CY; Zukerberg L; Lucarelli MJ; Hasserjian RP; Preffer FI; Harris NL
Am J Surg Pathol; 2007 Feb; 31(2):170-84. PubMed ID: 17255761
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
17. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
18. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
[TBL] [Abstract][Full Text] [Related]
19. Extranodal non-hodgkin lymphomas of the oral cavity and maxillofacial region: a clinical study of 58 cases and review of the literature.
Triantafillidou K; Dimitrakopoulos J; Iordanidis F; Gkagkalis A
J Oral Maxillofac Surg; 2012 Dec; 70(12):2776-85. PubMed ID: 22494508
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
